Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer

Kaira, Kyoichi; Yanagitani, Noriko; Sunaga, Noriaki; Imai, Hisao; Ono, Akiko; Koga, Yasuhiko; Hisada, Takeshi; Ishizuka, Tamotsu; Yamada, Masanobu

doi:10.3892/ol.2017.6259

Cited by 3 publications

(4 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the rates of adverse events were similar to those with docetaxel monotherapy , which has been recommended for elderly patients with advanced NSCLC. Moreover, the reported grade 3 or 4 hematological toxicities in elderly patients who received a combination of S‐1 with GEM were leukopenia (27.0%–29.0%), neutropenia (24.0%–45.9%), and anemia (0%–13.5%) . These results were equivalent to the findings of our study, indicating mild toxicities with S‐1 and PTX cotherapy.…”

supporting

confidence: 87%

“…Furthermore, previous studies have reported ORR, median PFS, and median OS of 27.0%–40.0%, 4.2– 6.4 months, and 12.9–17.8 months, respectively, in elderly patients who received cotherapy with S‐1 and GEM , and these results were not superior to those of our study (Fig. ).…”

contrasting

confidence: 79%

“…Therefore, non‐platinum‐based combination chemotherapies are promising for the treatment of elderly patients. In fact, non‐platinum‐based cotherapy such as S‐1 plus GEM has been reported to be effective and well tolerated .…”

mentioning

confidence: 99%

See 2 more Smart Citations

A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer

et al. 2018

View full text Add to dashboard Cite

Lessons Learned Coadministration of S‐1 and paclitaxel in elderly patients with advanced non‐small cell lung cancer showed favorable efficacy. Coadministration of S‐1 and paclitaxel in elderly patients with advanced non‐small lung cancer showed tolerable toxicity. Background Although monotherapy with cytotoxic agents including docetaxel or vinorelbine are recommended for elderly patients with advanced non‐small cell lung cancer (NSCLC), the outcome is not satisfactory. We evaluated the efficacy and safety of S‐1 and paclitaxel (PTX) as a first‐line cotreatment in elderly patients with advanced NSCLC. Methods Oral S‐1 was administered on days 1–14 every 3 weeks at 80, 100, and 120 mg per day for patients with body surface area < 1.25 m2, 1.25–1.5 m2, and > 1.5 m2, respectively. PTX was administered at 80 mg/m2 on days 1 and 8. The primary endpoint was response rate, and secondary endpoints were progression‐free survival (PFS), overall survival (OS), and safety. Results Seventeen patients were enrolled with response and disease control rates of 47.1% and 88.2%, respectively. Median PFS and OS were 5.6 and 35.0 months, respectively. Hematological grade 3 or 4 toxicities included leukopenia (55.8%), neutropenia (52.9%), febrile neutropenia (11.8%), and anemia (11.8%). Nonhematological grade 3 toxicities included stomatitis (23.5%), diarrhea (5.9%), and interstitial lung disease (5.9%), and grade 5 toxicities included interstitial lung disease (5.9%). Conclusion This S‐1 and PTX cotherapy dose and schedule showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC.

show abstract

supporting

confidence: 87%

contrasting

confidence: 79%

See 1 more Smart Citation

A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Gemcitabine, which has a broad spectrum of antitumor indications, was originally applied to solid tumors. 21,22 In the late 1990s, it started to be used for NHL. Gemcitabine as single-agent therapy proved to be effective, and gemcitabine-based chemotherapy for patients with PTCL had an ORR of 85%.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients

Sun

et al. 2020

Ther Adv Med Oncol

View full text Add to dashboard Cite

Aim: To compare the outcomes of GDPT [gemcitabine (G), cisplatin (D), prednisone (P), thalidomide (T)] versus CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) in treating newly diagnosed PTCL (peripheral T-cell lymphoma). Methods: An open-label prospective clinical trial with 153 newly diagnosed PTCL patients conducted between January 2010 and December 2018 was designed. Patients were randomly assigned to the GDPT (77 cases) and CHOP (76 cases) groups. Patients in each group were further divided into four subgroups: PTCL, not otherwise specified (PTCL-NOS); anaplastic large cell lymphoma (ALCL), angioimmunoblastic T cell lymphoma (AITL), and other types subgroup, in accordance with pathological patterns. Based on expression of RRM1, TOP2A, TUBB3, and ERCC1, patients were divided into groups with high and low gene expression levels. Clinical characteristics, side effects, efficacy, progression-free survival (PFS), and overall survival (OS) were compared. Results: There were no significant differences in the basic clinical features or side effects between the GDPT and CHOP groups. The overall response rate (ORR) of the GDPT group was better than that of the CHOP group (66.3% versus 50.0%, p = 0.042), as was the complete remission (CR) rate (42.9% versus 27.6%, p = 0.049). Patients in the GDPT group had a longer PFS and OS than the CHOP group. The 4-year PFS and OS rates in the GDPT group were both superior to those in the CHOP group (63.6% versus 53.0% for PFS, p = 0.035; 66.8% versus 53.6% for OS, p = 0.039). In the GDPT group, the difference in CR between the four subgroups was statistically significant ( p = 0.046). In the CHOP group, differences in both CR and ORR among the four subgroups were statistically significant ( p < 0.001 and p = 0.005, respectively). There were also statistically significant differences in CR between patients treated with CHOP and GDPT in the PTCL-NOS subgroup, AITL subgroup, and the other types subgroup ( p = 0.015; p = 0.003; p = 0.005, respectively). The data also showed a significant difference in OS among the four subgroups within the GDPT group ( p = 0.001). The OS of AITL was shorter than that of the other three subgroups. Four subgroups of CHOP showed a significant difference in PFS ( p = 0.019). There was no statistical association between responses and the gene expression levels of RRM1, ERCC1, TUBB3, and TOP2A. Conclusion: The GDPT group had better response rates and prolonged patient PFS and OS. As a promising new regimen, GDPT is expected to become the first-line therapy for PTCL. New agents should be applied to patients who do not achieve good responses with previous treatment, such as those diagnosed with angioimmunoblastic T cell lymphoma. Trial registration: This open randomized prospective clinical trial was registered at ClinicalTrials.gov (NCT01664975).

show abstract

Metabolic heterogeneity in early-stage lung adenocarcinoma revealed by RNA-seq and scRNA-seq

et al. 2023

View full text Add to dashboard Cite

Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer

Cited by 3 publications

References 26 publications

A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer

A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer

Outcomes of GDPT (gemcitabine, cisplatin, prednisone, thalidomide) versus CHOP in newly diagnosed peripheral T-cell lymphoma patients

Metabolic heterogeneity in early-stage lung adenocarcinoma revealed by RNA-seq and scRNA-seq

Contact Info

Product

Resources

About